bringing health insight

Treat the


Our pipeline of first-in-class oral therapies, which is built on our RBP4 (Retinol Binding Protein 4) platform technology, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.

First-in-Class Treatment for

Unmet Medical Need

Belite Bio™ is a San Diego-based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes.

Developed from our RBP4 platform technology, our lead candidate, LBS-008, has initiated its phase 3 for Stargardt disease, an inherited juvenile form of macular degeneration, and expects to initiate its phase 3 for dry age-related macular degeneration in 2022. LBS-008 has received Orphan Drug Designation in the US and Europe, as well as Rare Pediatric Disease Designation in the US.

Meet the team

LBS 008

Bringing Hope to

Incurable Blindness

Dry AMD / Stargardt Disease

Phase 3


LBS 009

Blocking the Path to

Metabolic disease

Non-Fatty Liver Disease / Type 2 Diabetes



Our Technology

Anti-RBP4 Platform

Our technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease and diabetes.

View Presentation


Jun 30 / 2021

Belite Bio Announces Start of LBS-008 Phase 3 Stargardt Disease Trial

Sep 16 / 2020

Lin BioScience, the parent company of Belite Bio raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt Disease

Apr 24 / 2019

Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease

Jan 21 / 2019

LBS-008 Recognized in UK NIHR’s Systematic Review of Treatments for Dry AMD and Stargardt Disease

Oct 2 / 2018

Belite Bio Initiates Phase 1 Study of LBS-008 in Australia

Sep 17 / 2018

FDA Grants Lin BioScience (Now Belite Bio™) Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease

Jan 10 / 2018

Lin BioScience (Now Belite Bio™) to Present Highlights for Phase I Clinical Candidates for the Treatment of Macular Degeneration and Cancer at the Biotech Showcase™ Annual Conference on January 10, 2018

Jan 5 / 2017

Lin Bioscience (Now Belite Bio™) Licenses First-in-Class Therapeutic Program to treat Dry Aged-Related Macular Degeneration from Columbia University in Collaboration with NIH

Patient Registry